Loading...
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis
Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019 (COVID-19) because of its involvement in driving cytokine storm. This systematic review and meta-analysis aimed to assess the safety and efficacy of anti-IL-6 signaling (anti-IL6/IL-6R/JAK) agents on COVID-19 bas...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7769953/ https://ncbi.nlm.nih.gov/pubmed/33384605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.615972 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|